NEJM 2025 (REDEFINE-2) Novo Nordisk FDA NDA submission announcement (December 18, 2025) Eli Lilly TRIUMPH-4 topline results (December 2025) Frequently Asked Questions Retatrutide produces higher weight loss at 28.7% versus CagriSema's 20.4%a difference of 21 pounds for a 250-pound person
[Correlation of intestinal mucosal injury with serum diamine oxidase]
This fact is evident, for example, in many human-specific diseases such as Alzheimer's, Parkinson's, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, cystic fibrosis, and hemophilia A, which do not appear in animals (202, 203)
What the 2026 Research Actually Shows A systematic review and meta-analysis published in Cureus in April 2026 pooled data from multiple randomised controlled trials of GLP-1 receptor agonists specifically in women with PMOS